Fig. 7: Targeting LSD1 enhances long-lasting response to anti-PD-1 treatment.

a Experimental design of administering GSK2879552 and PD-1 blocking antibodies. b Tumor growth curves of wildtype mice inoculated with MC38 tumor cells and treated with GSK2879552 or vehicle control in combination with anti-PD-1 or isotype control. c Individual tumor growth curves over time in response to anti-PD1 treatment alone or in combination with GSK2879552. d, e Percentages of TCF1⁺PD-1^int and TCF1^-PD-1^hi cells (d) or GzmB⁺ cells (e) in CD8⁺ TILs (Vehicle + Isotype, n = 6; GSK + Isotype, n = 6; Vehicle + anti-PD-1, n = 6; GSK + anti-PD-1, n = 7). f, g, Percentages (f, n = 9, 10, 6, 9, respectively) and cell numbers (g, n = 8, 9, 6, 5, respectively) of tumor-infiltrating CD3⁺CD4⁺ T cells and CD3⁺CD8⁺ T cells in gated CD45⁺ leukocytes. h, i Frequencies (h, n = 9, 10, 6, 9, respectively) and cell numbers (i, n = 8, 9, 6, 5, respectively) of CD8⁺TCF1^-TIM-3⁺ TILs. Data represent two independent experiments (b, d–i) or are pooled from two independent experiments (c), and are presented as mean ± SEM (b, d–i). Sample sizes are as indicated. Statistical significance was determined by two-way ANOVA (b) or two-sided unpaired t test (d–i). Source data are provided as a Source data file.